Through CRISPR screen implementing in the multiple myeloma cells treated with panobinostat, an oral broad-spectrum HDACi, genes encoding for the cell surface ABC transporters ABCB1 (MDR1/p-glycoprotein) have been identified as the most prominently reason for resistance to HDACi. This evidence concerns the gene ABCB1 and plasma cell myeloma.